Spyre Therapeutics (NASDAQ:SYRE) Research Coverage Started at Robert W. Baird

Research analysts at Robert W. Baird began coverage on shares of Spyre Therapeutics (NASDAQ:SYRE) in a research note issued on Thursday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $50.00 price target on the stock. Robert W. Baird’s price target indicates a potential upside of 39.74% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus lifted their target price on Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Wells Fargo & Company upgraded Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $12.00 to $35.00 in a research report on Friday, March 1st. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $41.00.

Spyre Therapeutics Price Performance

NASDAQ SYRE traded down $0.49 on Thursday, reaching $35.78. 196,820 shares of the company were exchanged, compared to its average volume of 323,984. The firm has a fifty day simple moving average of $36.20. The company has a market cap of $1.29 billion, a PE ratio of -0.48 and a beta of 2.93. Spyre Therapeutics has a fifty-two week low of $2.66 and a fifty-two week high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE) last posted its earnings results on Thursday, February 29th. The company reported ($2.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($1.80). Research analysts anticipate that Spyre Therapeutics will post -2.36 earnings per share for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).